Singh N K
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Clin Exp Hypertens. 1999 Jan-Feb;21(1-2):85-94. doi: 10.3109/10641969909068652.
Present study analyses nephroprotective effect of various therapeutic interventions at different stages of kidney involvement in diabetes mellitus. A MEDLINE search of past 10 years data on various experimental studies, controlled clinical trials, meta-analysis and editorials pertaining to nephroprotection in diabetes mellitus was made. Effect of various therapeutic interventions such as metabolic glycaemic control, restricted protein diet and antihypertensive drugs (especially ACE inhibitors) has been analysed on the progression of different stages of kidney involvement in diabetes mellitus such as normoalbuminuria, microalbuminuria, diabetic nephropathy and end stage renal disease (ESRD). An attempt has been made to analyse differential long-term impact of various therapeutic interventions in relation to type of diabetes mellitus (i.e., IDDM and NIDDM) and associated hypertension. Progression of IDDM patients having microalbuminuria or diabetic nephropathy with or without hypertension has improved during the past decade largely because of adequate glycaemic control and effective antihypertensive treatment with conventional drugs e.g. beta-blockers and calcium antagonists, and more so due to the use of ACE inhibitors e.g. captopril, enalapril etc. Superiority of ACE inhibitor tends to decline from normotensive stage to the degree of rise in systemic blood pressure. However, data in NIDDM patients suffering from diabetic nephropathy is incomplete and inconclusive.
本研究分析了在糖尿病肾脏病变不同阶段各种治疗干预措施的肾脏保护作用。对过去10年关于糖尿病肾脏保护的各种实验研究、对照临床试验、荟萃分析和社论的数据进行了MEDLINE检索。分析了各种治疗干预措施,如代谢血糖控制、限制蛋白饮食和抗高血压药物(尤其是血管紧张素转换酶抑制剂)对糖尿病肾脏病变不同阶段进展的影响,这些阶段包括正常白蛋白尿、微量白蛋白尿、糖尿病肾病和终末期肾病(ESRD)。已尝试分析各种治疗干预措施对糖尿病类型(即胰岛素依赖型糖尿病和非胰岛素依赖型糖尿病)及相关高血压的不同长期影响。在过去十年中,患有微量白蛋白尿或糖尿病肾病且伴有或不伴有高血压的胰岛素依赖型糖尿病患者的病情进展有了改善,这主要归功于血糖的充分控制以及使用传统药物(如β受体阻滞剂和钙拮抗剂)进行有效的抗高血压治疗,更得益于使用血管紧张素转换酶抑制剂(如卡托普利、依那普利等)。血管紧张素转换酶抑制剂的优势往往从血压正常阶段到全身血压升高程度逐渐下降。然而,关于非胰岛素依赖型糖尿病患者糖尿病肾病的数据并不完整且尚无定论。